Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment (2016)
Source: Journal of Enzyme Inhibition and Medicinal Chemistry. Unidade: FCF
Subjects: RELAÇÕES QUANTITATIVAS ENTRE ESTRUTURA QUÍMICA E ATIVIDADE BIOLÓGICA, RECEPTORES, ESQUIZOFRENIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PRIMI, Marina Candido et al. Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment. Journal of Enzyme Inhibition and Medicinal Chemistry, v. 31, n. 2, p. 283-294, 2016Tradução . . Disponível em: https://doi.org/10.3109/14756366.2015.1021250. Acesso em: 11 out. 2024.APA
Primi, M. C., Maltarollo, V. G., Magalhães, J. G. de, Sá, M. M. de, Rangel-Yagui, C. de O., & Trossini, G. H. G. (2016). Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment. Journal of Enzyme Inhibition and Medicinal Chemistry, 31( 2), 283-294. doi:10.3109/14756366.2015.1021250NLM
Primi MC, Maltarollo VG, Magalhães JG de, Sá MM de, Rangel-Yagui C de O, Trossini GHG. Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment [Internet]. Journal of Enzyme Inhibition and Medicinal Chemistry. 2016 ; 31( 2): 283-294.[citado 2024 out. 11 ] Available from: https://doi.org/10.3109/14756366.2015.1021250Vancouver
Primi MC, Maltarollo VG, Magalhães JG de, Sá MM de, Rangel-Yagui C de O, Trossini GHG. Convergent QSAR studies on a series of NK3 receptor antagonists for schizophrenia treatment [Internet]. Journal of Enzyme Inhibition and Medicinal Chemistry. 2016 ; 31( 2): 283-294.[citado 2024 out. 11 ] Available from: https://doi.org/10.3109/14756366.2015.1021250